Disclosed herein are methods and compositions for treating or preventing neuropathic pain in a subject, the method comprising administering to a subject a therapeutically effective amount of prolactin, or a functional variant thereof, wherein the functional variant comprises a peptide of formula (I) or a pharmaceutically acceptable salt thereof: R.sup.1-C-R-I-X.sub.1-X.sub.2-X.sub.3-X.sub.4-N-C-R.sup.2 (I) (SEQ ID NO:1) wherein X.sub.1 is an amino acid residue selected from isoleucine (I) and valine (V); X.sub.2 is an amino acid residue selected from histidine (H) and tyrosine (Y); X.sub.3 is an amino acid residue selected from aspartic acid (D) and asparagine (N); X.sub.4 is an amino acid Nresidue selected from asparagine (N) and serine (S); R.sup.1 is selected from the group consisting of YLKLLK, LKLLK, KLLK, LLK, LL, K or R.sup.1 is absent; and R.sup.2 is G (glycine), or R.sup.2 is absent.

The present invention relates to a stable, non-aqueous and ready-to-use injectable composition of a pharmaceutically active agent a pharmaceutically active agent or a pharmaceutically acceptable salt or a co-crystal thereof. The present invention also relates to a process for the preparation of the stable, non-aqueous and ready-to-use injectable composition of pharmaceutically active agent involving use of a non-solvent solvent system suitable for preparing a stabilized injectable composition comprising a pharmaceutically active agent a pharmaceutically active agent or a pharmaceutically acceptable salt or a co-crystal thereof. It is not required to reconstitute the injectable composition of pharmaceutically active agent with water prior to administration, thereby rendering it an easy-to-use injectable composition.

The present invention relates to a stable, non-aqueous and ready-to-use injectable composition of a pharmaceutically active agent a pharmaceutically active agent or a pharmaceutically acceptable salt or a co-crystal thereof. The present invention also relates to a process for the preparation of the stable, non-aqueous and ready-to-use injectable composition of pharmaceutically active agent involving use of a non-solvent solvent system suitable for preparing a stabilized injectable composition comprising a pharmaceutically active agent a pharmaceutically active agent or a pharmaceutically acceptable salt or a co-crystal thereof. It is not required to reconstitute the injectable composition of pharmaceutically active agent with water prior to administration, thereby rendering it an easy-to-use injectable composition.

The present disclosure relates generally to biocompatible nanoparticles, and in particular, neuroprotective nanoparticles comprising ciliary neurotrophic factor and/or oncostatin M. Methods for making and using the same are also provided.

The present disclosure relates generally to biocompatible nanoparticles, and in particular, neuroprotective nanoparticles comprising ciliary neurotrophic factor and/or oncostatin M. Methods for making and using the same are also provided.

A tissue graft construct, materials and methods for repairing an injured nerve in a patient. The tissue graft construct includes a band of biocompatible matrix and the hormone prolactin. The graft can be formed into a conduit and used to deliver the hormone prolactin directly at the site of nerve injury to promote healing.

Compositions comprising a taxane or taxoid, such as paclitaxel, and a protein, such as albumin or a metal-transferrin, such as gallium-transferrin, can be prepared by combining an aqueous protein solution with a second solution containing the taxane or taxoid, a non-ionic surfactant, and an alcohol; adjusting the pH of the combined solutions to between about 7.9 and about 8.3; and purifying the pH-adjusted solution to remove solutes having a molecular weight less than 10,000 Da. Such compositions can be prepared that are substantially free of non-ionic surfactants, such as Cremophor EL, and are useful in the treatment of cancers, such as breast cancer.

Compositions comprising a taxane or taxoid, such as paclitaxel, and a protein, such as albumin or a metal-transferrin, such as gallium-transferrin, can be prepared by combining an aqueous protein solution with a second solution containing the taxane or taxoid, a non-ionic surfactant, and an alcohol; adjusting the pH of the combined solutions to between about 7.9 and about 8.3; and purifying the pH-adjusted solution to remove solutes having a molecular weight less than 10,000 Da. Such compositions can be prepared that are substantially free of non-ionic surfactants, such as Cremophor EL, and are useful in the treatment of cancers, such as breast cancer.

Lipidated peptides, analogs of both forms of the prolactin-releasing peptide, PrRP31 and PrRP20, represent anorexigenic compounds that lower food intake and function in the brain after peripheral administration. The analogs PrRP31 and PrRP20 lipidated at the N-terminus by myristic or palmitic acids bind with high affinity to the endogenous receptor GPR10 in the rat pituitary cell line RC-4B/C and CHO cell line with transfected human receptor. These lipidated peptides also significantly decrease, in a dose-dependent manner, the food intake in fasted mice and have similar effects in comparable doses as centrally administered natural PrRP31, these effects are, however, stronger and longer lasting. Lipidation of an effective anorexigenic neuropeptide PrRP induces a central effect after peripheral administration and thus makes the lipidated analogs of PrRP a promising anti-obesity drug.

The present disclosure relates generally to biocompatible nanoparticles, and in particular, neuroprotective nanoparticles comprising ciliary neurotrophic factor and/or oncostatin M. Methods for making and using the same are also provided.